<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912873</url>
  </required_header>
  <id_info>
    <org_study_id>Hip Concentration Study</org_study_id>
    <nct_id>NCT00912873</nct_id>
  </id_info>
  <brief_title>Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks</brief_title>
  <official_title>Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to determine if the concentration of local anesthetic through a&#xD;
      catheter next to the nerves that go to the hip that is undergoing surgery, affects muscle&#xD;
      strength and sense of touch experienced after surgery. This study is looking at the varying&#xD;
      concentrations of local anesthetic placed through the catheter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      These results will help define the optimal concentration of local anesthetic used for&#xD;
      continuous peripheral nerve blocks and help guide future research in this clinically-relevant&#xD;
      area.&#xD;
&#xD;
      This investigation will be a randomized, observer-masked, controlled, parallel-arm,&#xD;
      human-subjects clinical trial.&#xD;
&#xD;
      Enrollment. Subjects will be patients undergoing hip arthroplasty. Study inclusion will be&#xD;
      proposed to eligible patients by the orthopedic surgery or anesthesia services or research&#xD;
      coordinator/assistant within four weeks prior to surgery. If a patient desires study&#xD;
      participation, written, informed consent will be obtained. Selection for inclusion will not&#xD;
      be based on gender, race, or socioeconomic status. The study population of interest includes&#xD;
      men and women of all races and socioeconomic status.&#xD;
&#xD;
      Preoperative Management. Prior to surgery but following written, informed consent, subjects&#xD;
      will have baseline endpoints measured. Patients will then have a perineural catheter placed&#xD;
      on the operative side using standard techniques currently used at UCSD, and previously&#xD;
      described. A 15 mL bolus of 2% mepivacaine with epinephrine (5 µg/mL) will be injected&#xD;
      through the catheter to demonstrate correct catheter placement and provide intraoperative&#xD;
      analgesia. Patients with a misplaced catheter indicated by a lack of sensory changes in the&#xD;
      surgical extremity within 15 min will have their catheter replaced or be withdrawn from the&#xD;
      study prior to randomization.&#xD;
&#xD;
      The remaining patients will then be randomized to one of two treatment groups: a&#xD;
      postoperative ropivacaine concentration of 0.1% or 0.4% (&quot;study infusate&quot;). Randomization&#xD;
      will be based on computer-generated codes that will be created and maintained by the&#xD;
      Investigational Drug Service. Randomization will be in blocks of four, and stratified by hip&#xD;
      arthroplasty procedure (either total or resurfacing). A portable electronic infusion pump&#xD;
      with study infusate will be attached to the perineural catheter. The basal rate and&#xD;
      patient-controlled bolus volume will depend upon the treatment group (note that the basal&#xD;
      rate and bolus volume differ for each concentration, but the total dose of local anesthetic&#xD;
      is the same for each):&#xD;
&#xD;
      Ropivacaine Concentration 0.1%: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4&#xD;
      mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)&#xD;
&#xD;
      Ropivacaine Concentration 0.4%: Basal Rate (3 mL/h); Basal Dose (12 mg/h); Bolus Volume (1&#xD;
      mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)&#xD;
&#xD;
      Intraoperative Management. Patients will receive a standardized general anesthetic with an&#xD;
      inhaled anesthetic in N2O and O2. These gasses will be titrated for a Bispectral Index of&#xD;
      40-60 in order to provide adequate anesthesia while minimizing postoperative recovery&#xD;
      duration. Esmolol and hydralazine will be used to provide hemodynamic stability, and opioids&#xD;
      administered if necessary (fentanyl in 25 µg increments). The ropivacaine infusion provided&#xD;
      by the Investigational Drug Service will be initiated using an infusion pump attached to the&#xD;
      perineural catheter. Just prior to emergence, IV morphine will be titrated for a respiratory&#xD;
      rate of 12-14. Upon emergence, patients will be taken to the recovery room and then to the&#xD;
      surgical ward.&#xD;
&#xD;
      Postoperative Pain Management. For the duration of the study, all patients will receive the&#xD;
      current usual and customary analgesics for hip arthroplasty patients at Hillcrest and&#xD;
      Thornton hospitals. Perineural infusions will be administered per standard UCSD routine:&#xD;
      continued administration until recommended discontinuation by the surgical service at which&#xD;
      time the catheter is removed by the acute pain service.&#xD;
&#xD;
      Outcome Measurements. We have selected measures that have established reliability and&#xD;
      validity. Staff blinded to treatment group assignment will perform all measures and&#xD;
      assessments. Preoperative measurements (performed prior to perineural catheter placement the&#xD;
      day of surgery): strength of the quadriceps femoris, hip adductors, and hip flexors; and&#xD;
      sensory level (measurement descriptions below). Postoperative measurements will be performed&#xD;
      the day following surgery as close to 8:00-9:00 and 12:30-13:30 as possible (logistics&#xD;
      occasionally preclude therapist evaluation at these exact hours).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Quadriceps Femoris Maximum Voluntary Isometric Contraction (MVIC)</measure>
    <time_frame>The study primary endpoint will be the difference in MVIC the morning following surgery compared with the preoperative MVIC, expressed as a percentage of the preoperative MVIC: (preop - postop ) / preop x 100.</time_frame>
    <description>Quadriceps femoris muscle strength evaluated using a portable, hand-held, isometric force dynamometer (MicroFET2, Lafayette Instrument Company, Lafayette, IN) to measure the maximum voluntary isometric contraction (MVIC) in a seated position. The study primary endpoint will be the difference in MVIC the morning following surgery compared with the preoperative MVIC, expressed as a percentage of the preoperative MVIC: (preop - postop ) / preop x 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ambulation 100-foot Walking Test</measure>
    <time_frame>Day following surgery</time_frame>
    <description>The 100-foot walking test simply measures the amount of time it takes patients to ambulate 100 feet. Patients will be allowed to slow or stop and rest during the walk, but will be asked to resume walking as soon as they feel they are able to.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Ambulation</measure>
    <time_frame>Day following surgery</time_frame>
    <description>Patients will be allowed to slow or stop and rest during the walk, but will be asked to resume walking as soon as they feel they are able to and go as far as they comfortable walking.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Hip Flexion</measure>
    <time_frame>Day following surgery</time_frame>
    <description>Evaluated in the supine position using a portable, hand-held, isometric force dynamometer (MicroFET2, Lafayette Instrument Company, Lafayette, IN). The endpoint will be the difference the morning following surgery compared with the preoperative value, expressed as a percentage of the preoperative value: (preop - postop ) / preop x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Resting Pain</measure>
    <time_frame>Day following surgery</time_frame>
    <description>Pain level evaluated using a verbal rating scale of 0-10, with 0=no pain and 10=worst imaginable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Dynamic Pain</measure>
    <time_frame>Day following surgery</time_frame>
    <description>Pain evaluated during physical therapy using a verbal rating scale of 0-10, with 0=no pain and 10=worst imaginable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Dynamic Pain</measure>
    <time_frame>Day following surgery</time_frame>
    <description>The worst pain experienced during physical therapy evaluated using a verbal rating scale of 0-10, with 0=no pain and 10=worst imaginable pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hip Arthroplasty</condition>
  <condition>Hip Pain</condition>
  <arm_group>
    <arm_group_label>0.1% Ropivicaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be given 0.1% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4% Ropivicaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given 0.4% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% Ropivacaine</intervention_name>
    <description>Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)</description>
    <arm_group_label>0.1% Ropivicaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.4% Ropivacaine</intervention_name>
    <description>Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (3 mL/h); Basal Dose (12 mg/h); Bolus Volume (1 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)</description>
    <arm_group_label>0.4% Ropivicaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary, unilateral hip arthroplasty&#xD;
&#xD;
          -  age greater than or equal to 18 years&#xD;
&#xD;
          -  postoperative analgesic plan includes perineural local anesthetic infusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  morbid obesity as defined by a body mass index greater than 40&#xD;
&#xD;
          -  chronic high dose opioid use&#xD;
&#xD;
          -  history of opioid abuse&#xD;
&#xD;
          -  neuro-muscular deficit of the ipsilateral femoral nerve and/or quadriceps muscle&#xD;
&#xD;
          -  vulnerable populations i.e., children, pregnant women, or prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian M Ilfeld, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ilfeld BM, Moeller LK, Mariano ER, Loland VJ, Stevens-Lapsley JE, Fleisher AS, Girard PJ, Donohue MC, Ferguson EJ, Ball ST. Continuous peripheral nerve blocks: is local anesthetic dose the only factor, or do concentration and volume influence infusion effects as well? Anesthesiology. 2010 Feb;112(2):347-54. doi: 10.1097/ALN.0b013e3181ca4e5d.</citation>
    <PMID>20098137</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <results_first_submitted>January 29, 2020</results_first_submitted>
  <results_first_submitted_qc>February 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2021</results_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Brian M. Ilfeld, MD, MS</investigator_full_name>
    <investigator_title>Associate Professor, In Residence</investigator_title>
  </responsible_party>
  <keyword>postoperative pain</keyword>
  <keyword>perineural catheter</keyword>
  <keyword>continuous peripheral nerve block</keyword>
  <keyword>posterior lumbar plexus</keyword>
  <keyword>hip surgery</keyword>
  <keyword>psoas compartment</keyword>
  <keyword>postoperative analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.1% Ropivicaine</title>
          <description>ropivicaine 0.1% infusion at 12 mL/hour</description>
        </group>
        <group group_id="P2">
          <title>0.4% Ropivicaine</title>
          <description>ropivicaine 0.4% infusion at 3 mL/hour</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.1% Ropivicaine</title>
          <description>ropivicaine 0.1% infusion at 3 mL/hour</description>
        </group>
        <group group_id="B2">
          <title>0.4% Ropivicaine</title>
          <description>ropivicaine 0.4% infusion at 3 mL/hour</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="3"/>
                    <measurement group_id="B2" value="52" spread="4"/>
                    <measurement group_id="B3" value="52.5" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Quadriceps Femoris Maximum Voluntary Isometric Contraction (MVIC)</title>
        <description>Quadriceps femoris muscle strength evaluated using a portable, hand-held, isometric force dynamometer (MicroFET2, Lafayette Instrument Company, Lafayette, IN) to measure the maximum voluntary isometric contraction (MVIC) in a seated position. The study primary endpoint will be the difference in MVIC the morning following surgery compared with the preoperative MVIC, expressed as a percentage of the preoperative MVIC: (preop - postop ) / preop x 100.</description>
        <time_frame>The study primary endpoint will be the difference in MVIC the morning following surgery compared with the preoperative MVIC, expressed as a percentage of the preoperative MVIC: (preop - postop ) / preop x 100.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.1% Ropivicaine</title>
            <description>0.1% Ropivicaine at 12 mL/h</description>
          </group>
          <group group_id="O2">
            <title>0.4% Ropivicaine</title>
            <description>0.4% Ropivicaine at 3 mL/h</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Quadriceps Femoris Maximum Voluntary Isometric Contraction (MVIC)</title>
          <description>Quadriceps femoris muscle strength evaluated using a portable, hand-held, isometric force dynamometer (MicroFET2, Lafayette Instrument Company, Lafayette, IN) to measure the maximum voluntary isometric contraction (MVIC) in a seated position. The study primary endpoint will be the difference in MVIC the morning following surgery compared with the preoperative MVIC, expressed as a percentage of the preoperative MVIC: (preop - postop ) / preop x 100.</description>
          <units>percentage change from baseline of MVIC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" spread="6.4"/>
                    <measurement group_id="O2" value="68" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ambulation 100-foot Walking Test</title>
        <description>The 100-foot walking test simply measures the amount of time it takes patients to ambulate 100 feet. Patients will be allowed to slow or stop and rest during the walk, but will be asked to resume walking as soon as they feel they are able to.</description>
        <time_frame>Day following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.1% Ropivicaine</title>
            <description>Patients will be given 0.1% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.&#xD;
0.1% Ropivacaine: Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)</description>
          </group>
          <group group_id="O2">
            <title>0.4% Ropivicaine</title>
            <description>Patients will be given 0.4% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.&#xD;
0.4% Ropivacaine: Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (3 mL/h); Basal Dose (12 mg/h); Bolus Volume (1 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)</description>
          </group>
        </group_list>
        <measure>
          <title>Ambulation 100-foot Walking Test</title>
          <description>The 100-foot walking test simply measures the amount of time it takes patients to ambulate 100 feet. Patients will be allowed to slow or stop and rest during the walk, but will be asked to resume walking as soon as they feel they are able to.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.3"/>
                    <measurement group_id="O2" value="5.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Afternoon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.3"/>
                    <measurement group_id="O2" value="3.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Ambulation</title>
        <description>Patients will be allowed to slow or stop and rest during the walk, but will be asked to resume walking as soon as they feel they are able to and go as far as they comfortable walking.</description>
        <time_frame>Day following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.1% Ropivicaine</title>
            <description>ropivicaine 0.1% infusion at 12 mL/hour</description>
          </group>
          <group group_id="O2">
            <title>0.4% Ropivicaine</title>
            <description>ropivicaine 0.4% infusion at 3 mL/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Total Ambulation</title>
          <description>Patients will be allowed to slow or stop and rest during the walk, but will be asked to resume walking as soon as they feel they are able to and go as far as they comfortable walking.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" spread="23"/>
                    <measurement group_id="O2" value="119" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>afternoon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223" spread="43"/>
                    <measurement group_id="O2" value="214" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Hip Flexion</title>
        <description>Evaluated in the supine position using a portable, hand-held, isometric force dynamometer (MicroFET2, Lafayette Instrument Company, Lafayette, IN). The endpoint will be the difference the morning following surgery compared with the preoperative value, expressed as a percentage of the preoperative value: (preop - postop ) / preop x 100.</description>
        <time_frame>Day following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.1% Ropivicaine</title>
            <description>ropivicaine 0.1% infusion at 12 mL/hour</description>
          </group>
          <group group_id="O2">
            <title>0.4% Ropivicaine</title>
            <description>ropivicaine 0.4% infusion at 3 mL/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Hip Flexion</title>
          <description>Evaluated in the supine position using a portable, hand-held, isometric force dynamometer (MicroFET2, Lafayette Instrument Company, Lafayette, IN). The endpoint will be the difference the morning following surgery compared with the preoperative value, expressed as a percentage of the preoperative value: (preop - postop ) / preop x 100.</description>
          <units>percentage change from baseline hip flex</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" spread="4"/>
                    <measurement group_id="O2" value="67" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>afternoon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="3"/>
                    <measurement group_id="O2" value="78" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Resting Pain</title>
        <description>Pain level evaluated using a verbal rating scale of 0-10, with 0=no pain and 10=worst imaginable pain</description>
        <time_frame>Day following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.1% Ropivicaine</title>
            <description>ropivicaine 0.1% infusion at 12 mL/hour</description>
          </group>
          <group group_id="O2">
            <title>0.4% Ropivicaine</title>
            <description>ropivicaine 0.4% infusion at 3 mL/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Resting Pain</title>
          <description>Pain level evaluated using a verbal rating scale of 0-10, with 0=no pain and 10=worst imaginable pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.4"/>
                    <measurement group_id="O2" value="3.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Dynamic Pain</title>
        <description>Pain evaluated during physical therapy using a verbal rating scale of 0-10, with 0=no pain and 10=worst imaginable pain</description>
        <time_frame>Day following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.1% Ropivicaine</title>
            <description>ropivicaine 0.1% infusion at 12 mL/hour</description>
          </group>
          <group group_id="O2">
            <title>0.4% Ropivicaine</title>
            <description>ropivicaine 0.4% infusion at 3 mL/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Average Dynamic Pain</title>
          <description>Pain evaluated during physical therapy using a verbal rating scale of 0-10, with 0=no pain and 10=worst imaginable pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="0.4"/>
                    <measurement group_id="O2" value="3.8" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>afternoon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.4"/>
                    <measurement group_id="O2" value="2.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Dynamic Pain</title>
        <description>The worst pain experienced during physical therapy evaluated using a verbal rating scale of 0-10, with 0=no pain and 10=worst imaginable pain</description>
        <time_frame>Day following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.1% Ropivicaine</title>
            <description>ropivicaine 0.1% infusion at 12 mL/hour</description>
          </group>
          <group group_id="O2">
            <title>0.4% Ropivicaine</title>
            <description>ropivicaine 0.4% infusion at 3 mL/hour</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Dynamic Pain</title>
          <description>The worst pain experienced during physical therapy evaluated using a verbal rating scale of 0-10, with 0=no pain and 10=worst imaginable pain</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="0.5"/>
                    <measurement group_id="O2" value="6.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>afternoon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.4"/>
                    <measurement group_id="O2" value="5.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through the day following surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.1% Ropivicaine</title>
          <description>ropivicaine 0.1% infusion at 12 mL/hour</description>
        </group>
        <group group_id="E2">
          <title>0.4% Ropivicaine</title>
          <description>ropivicaine 0.4% infusion at 3 mL/hour</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Ilfeld, MD, MS</name_or_title>
      <organization>University California San Diego</organization>
      <phone>(858) 822-0776</phone>
      <email>bilfeld@health.ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

